{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:55:15Z","timestamp":1793321715867,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>Nonalcoholic steatohepatitis (NASH) is a strong risk factor for end-stage liver disease. Trigonelline (TG) is a plant alkaloid with anti-oxidant, anti-dyslipidemic, and anti-insulin resistance activities. Everolimus (EV), a conventional drug and an mTOR inhibitor, has been demonstrated to improve metabolic outcomes. The synergistic effect of the co-treatment of TG and EV against NASH conditions remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>We have developed a fast food (FF)-diet and thioacetamide-induced chronic steatohepatitis in a C57BL\/6J mice model of 24 weeks duration. We have evaluated the synergistic protective effect of TG and EV at reduced doses to avoid any undesired toxic manifestations of the FF and thioacetamide. The study was demonstrated by comparative analysis across different groups after 24 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Co-exposure to FF diet and thioacetamide resulted in chronic steatohepatitis, evident by focal necrosis, bridging fibrosis, loss of liver architecture, and excessive collagen deposition. Protein and gene analysis revealed enhanced\n                      <jats:italic toggle=\"yes\">de novo<\/jats:italic>\n                      lipogenesis (SREBP-1, PPAR-\u01b3, CD36), inflammation (interleukin-6, tumor necrosis factor, CYP2E1), fibrosis (transforming growth factor beta, alpha-smooth muscle actin, tissue inhibitors of metalloproteinases-1), and extracellular matrix deposition (MMP-1, Col1A1). TG + EV at reduced doses showed marked synergistic effects in preventing inflammation, fibrosis, and lipogenesis markers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>This study provides a novel 24-week FF diet and thioacetamide-induced murine NASH model for possible preclinical drug discovery studies. Furthermore, our treatment regimen discovered the synergistic effect of TG and EV at reduced doses in preventing chronic steatohepatitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_323_23","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T11:00:18Z","timestamp":1753095618000},"page":"234-241","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Co-treatment of trigonelline and everolimus synergistically prevented chronic steatohepatitis induced by fast food diet and thioacetamide in a novel murine nonalcoholic steatohepatitis model"],"prefix":"10.4103","volume":"57","author":[{"given":"Raghu Rai","family":"Sharma","sequence":"first","affiliation":[{"name":"Biological Sciences, Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India"},{"name":"Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Love","family":"Sharma","sequence":"additional","affiliation":[{"name":"Biological Sciences, Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India"},{"name":"Business Development and Information Sciences and Technology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Rashid","sequence":"additional","affiliation":[{"name":"Department of Hospital Administration, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aalim Maqsood","family":"Bhat","sequence":"additional","affiliation":[{"name":"Biological Sciences, Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India"},{"name":"Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Gupta","sequence":"additional","affiliation":[{"name":"Biological Sciences, Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India"},{"name":"Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh Abdullah","family":"Tasduq","sequence":"additional","affiliation":[{"name":"Biological Sciences, Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India"},{"name":"Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev-pharmtox-010617-052545","article-title":"Nonalcoholic steatohepatitis (NASH) and hepatic fibrosis: Emerging therapies","volume":"58","author":"Wattacheril","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R2-20260422","first-page":"207","article-title":"Non-alcoholic steatohepatitis: The therapeutic challenge of a global epidemic","volume":"25","author":"Mouzaki","year":"2012","journal-title":"Ann Gastroenterol"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.surg.2014.06.075","article-title":"Increasing prevalence of nonalcoholic steatohepatitis as an indication for liver transplantation","volume":"156","author":"Quillin","year":"2014","journal-title":"Surgery"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: An overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol Commun"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/gut.2003.019984","article-title":"Long term prognosis of fatty liver: Risk of chronic liver disease and death","volume":"53","author":"Dam-Larsen","year":"2004","journal-title":"Gut"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrd.2016.188","article-title":"Nonalcoholic steatohepatitis (NASH) drugs market","volume":"15","author":"Cassidy","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11010-014-2152-x","article-title":"Trigonelline and diosgenin attenuate ER stress, oxidative stress-mediated damage in pancreas and enhance adipose tissue PPAR\u03b3 activity in type 2 diabetic rats","volume":"396","author":"Tharaheswari","year":"2014","journal-title":"Mol Cell Biochem"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.fct.2018.09.011","article-title":"Trigonelline prevents high cholesterol and high fat diet induced hepatic lipid accumulation and lipo-toxicity in C57BL\/6J mice, via restoration of hepatic autophagy","volume":"121","author":"Sharma","year":"2018","journal-title":"Food Chem Toxicol"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.toxlet.2019.01.001","article-title":"Thioacetamide potentiates high cholesterol and high fat diet induced steato-hepatitic changes in livers of C57BL\/6J mice: A novel eight weeks model of fibrosing NASH","volume":"304","author":"Sharma","year":"2019","journal-title":"Toxicol Lett"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/lt.20707","article-title":"Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results","volume":"12","author":"Levy","year":"2006","journal-title":"Liver Transpl"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"113403","DOI":"10.18632\/oncotarget.15194","article-title":"Long-term administration of tacrolimus and everolimus prevents high cholesterol-high fructose-induced steatosis in C57BL\/6J mice by inhibiting de-novo lipogenesis","volume":"8","author":"Love","year":"2017","journal-title":"Oncotarget"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3727\/105221617X15093707969658","article-title":"Updates on dietary models of nonalcoholic fatty liver disease: Current studies and insights","volume":"18","author":"Stephenson","year":"2018","journal-title":"Gene Expr"},{"key":"R13-20260422","first-page":"626","article-title":"Reversal of hepatotoxin-induced pre-fibrogenic events by Emblica officinalis \u2013 A histological study","volume":"45","author":"Mir","year":"2007","journal-title":"Indian J Exp Biol"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/0023677215573040","article-title":"Standard operating procedures in experimental liver research: Thioacetamide model in mice and rats","volume":"49","author":"Wallace","year":"2015","journal-title":"Lab Anim"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-230X-14-89","article-title":"Fast food diet with CCl4 micro-dose induced hepatic-fibrosis \u2013 A novel animal model","volume":"14","author":"Chheda","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.3748\/wjg.v16.i42.5286","article-title":"Histopathology of nonalcoholic fatty liver disease","volume":"16","author":"Brunt","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/01.mog.0000182863.96421.47","article-title":"Role of inflammation in nonalcoholic steatohepatitis","volume":"21","author":"Choi","year":"2005","journal-title":"Curr Opin Gastroenterol"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10799893.2020.1726952","article-title":"Inevitable role of TGF-\u03b21 in progression of nonalcoholic fatty liver disease","volume":"40","author":"Nair","year":"2020","journal-title":"J Recept Signal Transduct Res"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jhep.2018.08.013","article-title":"The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options","volume":"69","author":"Younossi","year":"2018","journal-title":"J Hepatol"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/bj3010193","article-title":"Interleukin-6, but not tumour necrosis factor-\u03b1, increases lipogenesis in rat hepatocyte primary cultures","volume":"301","author":"Brass","year":"1994","journal-title":"Biochem J"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.yexmp.2015.11.008","article-title":"Induction of CYP2E1 in non-alcoholic fatty liver diseases","volume":"99","author":"Aljomah","year":"2015","journal-title":"Exp Mol Pathol"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0168-8278(97)80454-0","article-title":"Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease","volume":"26","author":"Murawaki","year":"1997","journal-title":"J Hepatol"},{"key":"R24-20260422","doi-asserted-by":"crossref","first-page":"101428","DOI":"10.1016\/j.molmet.2021.101428","article-title":"CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing","volume":"57","author":"Zeng","year":"2022","journal-title":"Mol Metab"},{"key":"R25-20260422","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1208\/s12248-016-9919-9","article-title":"Dual outcomes of rosiglitazone treatment on fatty liver","volume":"18","author":"Gao","year":"2016","journal-title":"AAPS J"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_323_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:55:56Z","timestamp":1786647356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_323_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_323_23","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2023-05-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}